268 related articles for article (PubMed ID: 26672755)
1. Partial PTEN deletion is linked to poor prognosis in breast cancer.
Lebok P; Kopperschmidt V; Kluth M; Hube-Magg C; Özden C; B T; Hussein K; Mittenzwei A; Lebeau A; Witzel I; Wölber L; Mahner S; Jänicke F; Geist S; Paluchowski P; Wilke C; Heilenkötter U; Simon R; Sauter G; Terracciano L; Krech R; von d Assen A; Müller V; Burandt E
BMC Cancer; 2015 Dec; 15():963. PubMed ID: 26672755
[TBL] [Abstract][Full Text] [Related]
2. 8p deletion is strongly linked to poor prognosis in breast cancer.
Lebok P; Mittenzwei A; Kluth M; Özden C; Taskin B; Hussein K; Möller K; Hartmann A; Lebeau A; Witzel I; Mahner S; Wölber L; Jänicke F; Geist S; Paluchowski P; Wilke C; Heilenkötter U; Simon R; Sauter G; Terracciano L; Krech R; von der Assen A; Müller V; Burandt E
Cancer Biol Ther; 2015; 16(7):1080-7. PubMed ID: 25961141
[TBL] [Abstract][Full Text] [Related]
3. p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer.
Lebok P; Roming M; Kluth M; Koop C; Özden C; Taskin B; Hussein K; Lebeau A; Witzel I; Wölber L; Geist S; Paluchowski P; Wilke C; Heilenkötter U; Müller V; Schmalfeldt B; Simon R; Sauter G; Terracciano L; Krech RH; von der Assen A; Burandt E
Oncotarget; 2016 Dec; 7(49):81322-81331. PubMed ID: 27835607
[TBL] [Abstract][Full Text] [Related]
4. 6q deletion is frequent but unrelated to patient prognosis in breast cancer.
Lebok P; Bönte H; Kluth M; Möller-Koop C; Witzel I; Wölber L; Paluchowski P; Wilke C; Heilenkötter U; Müller V; Schmalfeldt B; Simon R; Sauter G; Terracciano L; Krech RH; von der Assen A; Burandt E
Breast Cancer; 2022 Mar; 29(2):216-223. PubMed ID: 34625909
[TBL] [Abstract][Full Text] [Related]
5. Deletion of 8p is an independent prognostic parameter in prostate cancer.
Kluth M; Amschler NN; Galal R; Möller-Koop C; Barrow P; Tsourlakis MC; Jacobsen F; Hinsch A; Wittmer C; Steurer S; Krech T; Büscheck F; Clauditz TS; Beyer B; Wilczak W; Graefen M; Huland H; Minner S; Schlomm T; Sauter G; Simon R
Oncotarget; 2017 Jan; 8(1):379-392. PubMed ID: 27880722
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
[TBL] [Abstract][Full Text] [Related]
7. PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.
Stern HM; Gardner H; Burzykowski T; Elatre W; O'Brien C; Lackner MR; Pestano GA; Santiago A; Villalobos I; Eiermann W; Pienkowski T; Martin M; Robert N; Crown J; Nuciforo P; Bee V; Mackey J; Slamon DJ; Press MF
Clin Cancer Res; 2015 May; 21(9):2065-74. PubMed ID: 25649019
[TBL] [Abstract][Full Text] [Related]
8. Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancer.
Kluth M; Runte F; Barow P; Omari J; Abdelaziz ZM; Paustian L; Steurer S; Christina Tsourlakis M; Fisch M; Graefen M; Tennstedt P; Huland H; Michl U; Minner S; Sauter G; Simon R; Adam M; Schlomm T
Int J Cancer; 2015 Nov; 137(10):2354-63. PubMed ID: 26009879
[TBL] [Abstract][Full Text] [Related]
9. Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer.
Ettl T; Baader K; Stiegler C; Müller M; Agaimy A; Zenk J; Kühnel T; Gosau M; Zeitler K; Schwarz S; Brockhoff G
Br J Cancer; 2012 Feb; 106(4):719-26. PubMed ID: 22240798
[TBL] [Abstract][Full Text] [Related]
10. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
[TBL] [Abstract][Full Text] [Related]
11. A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer.
Troyer DA; Jamaspishvili T; Wei W; Feng Z; Good J; Hawley S; Fazli L; McKenney JK; Simko J; Hurtado-Coll A; Carroll PR; Gleave M; Lance R; Lin DW; Nelson PS; Thompson IM; True LD; Brooks JD; Squire JA
Prostate; 2015 Aug; 75(11):1206-15. PubMed ID: 25939393
[TBL] [Abstract][Full Text] [Related]
12. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.
Esteva FJ; Guo H; Zhang S; Santa-Maria C; Stone S; Lanchbury JS; Sahin AA; Hortobagyi GN; Yu D
Am J Pathol; 2010 Oct; 177(4):1647-56. PubMed ID: 20813970
[TBL] [Abstract][Full Text] [Related]
13. Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling.
Sajjadi E; Venetis K; Piciotti R; Gambini D; Blundo C; Runza L; Ferrero S; Guerini-Rocco E; Fusco N
BMC Cancer; 2021 Oct; 21(1):1152. PubMed ID: 34706703
[TBL] [Abstract][Full Text] [Related]
14. Loss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancer.
Beg S; Siraj AK; Prabhakaran S; Jehan Z; Ajarim D; Al-Dayel F; Tulbah A; Al-Kuraya KS
Breast Cancer Res Treat; 2015 Jun; 151(3):541-53. PubMed ID: 25981902
[TBL] [Abstract][Full Text] [Related]
15. Amplification of 8q21 in breast cancer is independent of MYC and associated with poor patient outcome.
Choschzick M; Lassen P; Lebeau A; Marx AH; Terracciano L; Heilenkötter U; Jaenicke F; Bokemeyer C; Izbicki J; Sauter G; Simon R
Mod Pathol; 2010 Apr; 23(4):603-10. PubMed ID: 20139910
[TBL] [Abstract][Full Text] [Related]
16. Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma.
Tokunaga E; Oki E; Kimura Y; Yamanaka T; Egashira A; Nishida K; Koga T; Morita M; Kakeji Y; Maehara Y
Breast Cancer Res Treat; 2007 Mar; 101(3):249-57. PubMed ID: 17006756
[TBL] [Abstract][Full Text] [Related]
17. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
[TBL] [Abstract][Full Text] [Related]
18. MGMT and PTEN as potential prognostic markers in breast cancer.
Neto JC; Ikoma MM; Carvalho KC; Vassallo J; De Brot M; Gobbi H; Soares FA; Rocha RM
Exp Mol Pathol; 2012 Feb; 92(1):20-6. PubMed ID: 22019339
[TBL] [Abstract][Full Text] [Related]
19. Prognostic relevance of gene amplifications and coamplifications in breast cancer.
Al-Kuraya K; Schraml P; Torhorst J; Tapia C; Zaharieva B; Novotny H; Spichtin H; Maurer R; Mirlacher M; Köchli O; Zuber M; Dieterich H; Mross F; Wilber K; Simon R; Sauter G
Cancer Res; 2004 Dec; 64(23):8534-40. PubMed ID: 15574759
[TBL] [Abstract][Full Text] [Related]
20. PTEN deletions are related to disease progression and unfavourable prognosis in early bladder cancer.
Cordes I; Kluth M; Zygis D; Rink M; Chun F; Eichelberg C; Dahlem R; Fisch M; Höppner W; Wagner W; Doh O; Terracciano L; Simon R; Wilczak W; Sauter G; Minner S
Histopathology; 2013 Nov; 63(5):670-7. PubMed ID: 24004025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
